The Beijing branch of China’s National Health Commission said a combination of lopinavir and ritonavir, sold under the brand name Kaletra by AbbVie, is part of its latest treatment plan for patients infected by the Coronavirus, which has killed at 81 people in China and sickened more than 2,800 worldwide.
After breaking out of the downtrend, ABBV is coming back to retest the channel, support area and weekly 50 moving average.
In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 9. For comparison, its industry has an average Forward P/E of 15.48, which means ABBV is trading at a discount to the group.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be February 7, 2020. In that report, analysts expect ABBV to post earnings of $2.20 per share. This would mark year-over-year growth of 15.79%
After breaking out of the downtrend, ABBV is coming back to retest the channel, support area and weekly 50 moving average.
In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 9. For comparison, its industry has an average Forward P/E of 15.48, which means ABBV is trading at a discount to the group.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be February 7, 2020. In that report, analysts expect ABBV to post earnings of $2.20 per share. This would mark year-over-year growth of 15.79%